Gentian Diagnostics ASA OSL:GENT:
VATNE CAPITAL REDUCES INDIRECT OWNERSHIP IN CO FROM 13.65% TO 0%
Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
Gentian Diagnostics ASA on 6ix
Earlier from Gentian Diagnostics
- Serum calprotectin - marker of systemic inflammation and disease activity
- GENT: Q1 saw stable sales, NT-proBNP project termination, and a focus on new growth opportunities
- Gentian Diagnostics: Invitation to presentation of first quarter results
- Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories
- Gentian Diagnostics ASA - Registration of share capital increase
Later from Gentian Diagnostics
- Join our R&D Team in Gothenburg
- Essange Reagents And Gentian Diagnostics Announce Collaboration Agreement
- Gentian Diagnostics - Second quarter 2026 report
Follow Gentian Diagnostics into a list and get an email when it puts out news.
Follow Gentian Diagnostics